Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and ...

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

The company's shares were trading at $740.80, on track for their worst single-day decline in nearly four years. Lilly's stock ...

Management notes that it's 45% more than Lilly got in Q4 2023, and that fully 40% of its Q4 money haul, $5.4 billion, will ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...